Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report
- 30 September 2002
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 38 (13) , 1730-1738
- https://doi.org/10.1016/s0959-8049(02)00144-2
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter TrialJournal of Clinical Oncology, 2001
- Phase II Study of Docetaxel, Doxorubicin, and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast CancerJournal of Clinical Oncology, 2001
- Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-OverJournal of Clinical Oncology, 2000
- Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.Journal of Clinical Oncology, 1995
- Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): Not simply two of a kindAnnals of Oncology, 1994
- Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience.Journal of Clinical Oncology, 1989
- Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.Journal of Clinical Oncology, 1987
- Combination chemotherapy and adriamycin in patients with advanced breast cancer.A Southwest Oncology Group studyCancer, 1976